DOI: https://doi.org/10.14710/jbtr.v10i2.20330

Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios are Predictors of Lung Malignancy

1Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sebelas Maret , Indonesia

2Dr. Moewardi General Hospital, Indonesia

3Department of Public Health and Community Medicine, Faculty of Medicine, Universitas Syiah Kuala, Indonesia

Received: 30 Aug 2023; Accepted: 19 Apr 2024; Available online: 30 Aug 2023; Published: 30 Aug 2024.
Open Access Copyright (c) 2024 Journal of Biomedicine and Translational Research
Creative Commons License This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Citation Format:
Abstract

Background: Inflammatory cells play an essential role in the neoplastic process by stimulating cancer proliferation, survival, and migration. Neutrophil-lymphocyte and platelet-lymphocyte levels can be used as the inflammatory tissue damage markers in cancer patients.

Objective: This study aimed to analyze the increase of neutrophil-lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) as the predictive factors for lung malignancy.

Methods: This study was a diagnostic cross-sectional study design in lung tumor patients at Dr. Moewardi Hospital Surakarta from August to October 2018. The subjects (60) were selected with consecutive sampling who take lung cancer diagnostic tests and divided into two groups of patients with lung tumors (30) and healthy (30) as control. The diagnostic procedures and neutrophil–lymphocyte and platelet–lymphocyte ratios calculation were performed on both groups. The optimum cutoff values for the NLR and PLR were calculated from the receiver operating curve analysis.

Results: The statistical test found a significant difference in the neutrophil–lymphocyte and platelet–lymphocyte ratios between cancer patients and control (p = 0.0000). The lung cancer group exhibited an increase in the NLR with 90.0% sensitivity and 96.7% specificity with a cutoff of 2.71. The platelet–lymphocyte ratio had a cutoff of 136.63 at 83.3% sensitivity and 80.0% specificity.

Conclusion: The increase of neutrophil-lymphocyte and the platelet-lymphocyte ratio can be used as a predictive predictor of lung malignancy.

Note: This article has supplementary file(s).

Fulltext View|Download |  Cover Letter
Cover Letter
Subject
Type Cover Letter
  Download (19KB)    Indexing metadata
 common.other
Suggest Reviewer
Subject
Type Other
  Download (11KB)    Indexing metadata
Keywords: leukocyte; lymphocyte; lung tumor; malignancy; neutrophil; platelet.

Article Metrics:

Article Info
Section: Original Research Articles
Language : EN
Recent articles
Psychotherapy Supportive Practice For Borderline Personality Disorder (A Clinical Module Development) Antibiotic-Resistant Phenotype and Genotype of S. suis serotype 2 (SS2) Isolated from Humans in Bali, Indonesia Sorghum Tempeh on Cholesterol Levels and Histopathology of Aorta in High-Fat Diet-Induced Rat Model More recent articles
  1. Detterbeck FC, Lewis SZ, Diekemper R, Addrizzo-Harris D, Alberts WM. Executive Summary: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:7S-37S. https://doi.org/10.1378/chest.12-2377
  2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61: 69-90. https://doi.org/10.3322/caac.20107
  3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29. https://doi.org/10.3322/caac.20138
  4. Gomes M, Teixeira AL, Coelho A, Araujo A, Medeiros R. Inflammation and lung cancer oxidatives Stress, ROS, and DNA damage. In: Ahmad SI, eds. Reactive Oxygen Species in Biology and Human Health. London: CRC Press; 2016
  5. Nikolić I, Kukulj S, Samaržija M, Jeleč V, Žarak M, Orehovec B, Taradi I, Romic D, Kolak T, Patrlj L. Neutrophil-to-lymphocytes and platelet-to-lymphocytes ratio help identify patients with lung cancer, but don't differentiate between lung cancer subtypes. Croat Med J. 2016; 57: 287–92. https://doi.org/10.3325/cmj.2016.57.287
  6. Heron M. Deaths: Leading causes for 2013. Natl Vital Stat Rep 2016; 65 :1-94
  7. Yoon HI, Kwon OR, Kang KN, Shin YS, Shin HS, Yeon EH, Kwon KY, Hwang I, Jeon YK, Kim Y, Kim CW. Diagnostic value of combining tumors and inflammatory markers in lung cancer. J Cancer Prev. 2016;21:187–193. https://doi.org/10.15430/JCP.2016.21.3.187
  8. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;19(420):860-867. https://doi.org/10.1038/nature01322
  9. Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A. Are neutrophils/lymphocytes and platelets / lymphocytes rates in patients with non-small cell lung cancer associated with treatment response and prognosis?. Asian Pac J Cancer Prev. 2013;14:5237–42. https://doi.org/10.7314/apjcp.2013.14.9.5237
  10. Karagöz B, Alacacioǧlu A, Bilgi O, Demirci H, Özgün A, Erikçi AA, Sayan O, Yilmaz B, Kandemir EG. Platelet count and platelet distribution width increases in lung cancer patients. Anatol J Clin Investig. 2009;3:32–4
  11. Mikogami T, Kunimura T, Omatsu M, Shiokawa A, Nagai T, Hirota Y, Koji S, Ohike N, Kitami A, Suzuki T. Neutrophil-rich pulmonary carcinoma: Clinicopathological characteristicsand cytokine expression and their relationship with lymph node metastasis. Showa Univ J Med Sci. 2014;26:9-16. https://doi.org/10.15369/sujms.26.9
  12. Aldarouish M, Wang C. Trends and advances in tumor immunology and lung cancer immunotherapy. J Exp Clin Cancer Res.2016;35:157. https://doi.org/10.1186/s13046-016-0439-3
  13. Indonesian Ministry of Health. National Guidelines for Medical Services: Lung Cancer. Jakarta: Indonesian Ministry of Health; 2017. p. 1–75. [In Indonesia]
  14. Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends. J Thorac Oncol, 2008;3:819–31. https://doi.org/10.1097/JTO.0b013e31818020eb
  15. Hruba F, Fabiánová E, Bencko V, Cassidy A, Lissowska J, Mates D, Rudnai P, Zaridze D, Foretova L, Janout V, Dabrowska NS, Brennan P, Boffrtta P. Socioeconomic indicators and risk of lung cancer in central and eastern Europe. Cent Eur J Public Health. 2009;17: 115–21
  16. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J, 2009;34:380-386. https://doi.org/10.1183/09031936.00144208
  17. Rahal Z, El Nemr S, Sinjab A, Chami H, Tfayli A, Kadara H. Smoking and lung cancer: A geo-regional perspective. Front Oncol. 2017;7:194. https://doi.org/10.3389/fonc.2017.00194
  18. Zhu H, Zhang S. Body mass index and lung cancer risk in never smokers: a meta-analysis. BMC Cancer. 2018;18:635. https://doi.org/10.1186/s12885-018-4543-y
  19. Iyer S, Roughley A, Rider A, Taylor-Stokes G. The symptom burden of non-small cell lung cancer in the USA: A real-world cross-sectional study. Support Care Cancer. 2014;22:181-7. https://doi.org/10.1007/s00520-013-1959-4
  20. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646–74. https://doi.org/10.1016/j.cell.2011.02.013
  21. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. 2010;185:2273–
  22. https://doi.org/10.4049/jimmunol.1000901
  23. Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer 2016;16:431–46. https://doi.org/10.1038/nrc.2016.52
  24. Zhang X, Ran Y. Prognostic role of elevated platelet count in patients with lung cancer: a systematic review and meta-analysis. Int J Clin Exp Med. 2015;8:5379–87
  25. Peng B, Wang YH, Liu YM, Ma LX. Prognostic significance of the neutrophil to lymphocyte ratio in patients with non-small cell lung cancer: A systemic review and meta-analysis. Int J Clin Exp Med. 2015;8:3098-106
  26. Kargl J, Busch SE, Yang GHY, Kim KH, Hanke ML, Metz HE, Hubbard JJ, Lee SM, Madtes DK, McIntosh MW, Houghton AM. Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun. 2017;8:14381. https://doi.org/10.21037/jtd.2017.04.55
  27. Kemal Y, Yucel I, Ekiz K, Demirag G, Yilmaz B, Teker F, Ozdemir M. Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis. Asian Pac J Cancer Prev. 2014;15:2651-2654. https://doi.org/10.7314/apjcp.2014.15.6.2651

Last update:

No citation recorded.

Last update:

No citation recorded.